CaMK4-dependent activation of AKT/mTOR and CREM-α underlies autoimmunity-associated Th17 imbalance

Tomohiro Koga,1 Christian M. Hedrich,1,2 Masayuki Mizui,1 Nobuya Yoshida,1 Kotaro Otomo,1 Linda A. Lieberman,1 Thomas Rauen,1,3 José C. Crispín,1 and George C. Tsokos1

1Division of Rheumatology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA. 2Pediatric Rheumatology and Immunology, University Children’s Hospital Dresden, Dresden, Germany. 3Department of Nephrology and Clinical Immunology, RWTH University of Aachen, Aachen, Germany.

Introduction

IL-17–producing CD4+ T cells are defined by specific developmental and functional features that are distinct from those of “classical” Th1 and Th2 cells (1, 2). Th17 cells produce primarily two members of the IL-17 family, IL-17A and IL-17F, which promote local chemokine production to recruit monocytes and neutrophils to sites of inflammation (3). By amplifying inflammation, Th17 cells are thought to play a key role in the development and pathogenesis of various autoimmune diseases, including MS, rheumatoid arthritis, psoriasis, and SLE (4–8). Tregs, defined by constitutive expression of the high-affinity IL-2 receptor CD25 and the multifunctional serine/threonine kinase that regulates several cellular processes, including gene expression (18). We have reported previously that CaMK4 is abnormally increased in T cells from patients with SLE and healthy individuals inhibited Th17 differentiation through reduction of IL17A and IL17F mRNA. Collectively, our results suggest that CaMK4 inhibition has potential as a therapeutic strategy for Th17-driven autoimmune diseases.

Tissue inflammation in several autoimmune diseases, including SLE and MS, has been linked to an imbalance of IL-17–producing Th (Th17) cells and Tregs; however, the factors that promote Th17-driven autoimmunity are unclear. Here, we present evidence that the calcium/calmodulin-dependent protein kinase IV (CaMK4) is increased and required during Th17 cell differentiation. Isolation of naïve T cells from a murine model of lupus revealed increased levels of CaMK4 following stimulation with Th17-inducing cytokines but not following Treg, Th1, or Th2 induction. Furthermore, naïve T cells from mice lacking CaMK4 did not produce IL-17. Genetic or pharmacologic inhibition of CaMK4 decreased the frequency of IL-17–producing T cells and ameliorated EAE and lupus-like disease in murine models. Inhibition of CaMK4 reduced Il17 transcription through decreased activation of the cAMP response element modulator α (CREM-α) and reduced activation of the AKT/mTOR pathway, which is known to enhance Th17 differentiation. Importantly, silencing CaMK4 in T cells from patients with SLE and healthy individuals inhibited Th17 differentiation through reduction of IL17A and IL17F mRNA. Collectively, our results suggest that CaMK4 inhibition has potential as a therapeutic strategy for Th17-driven autoimmune diseases.

Conflict of interest: The authors have declared that no conflict of interest exists.

Citation for this article: J Clin Invest. 2014;124(5):2234–2245. doi:10.1172/JCI73411.
CaMK4 is induced during Th17 differentiation. (A) Western blot analysis of CaMK4 and phospho-STAT3 in unstimulated (UN) cells from MRL/lpr mice and cells stimulated under Th0, Th17, and Treg conditions. Cumulative data of densitometry is also shown (*P < 0.05; mean ± SEM; n = 3). (B) Real-time PCR analysis of Camk4 mRNA in naïve CD4+ T cells from MRL/lpr mice stimulated 6 hours in Th0, Th1, Th2, Th17, or Treg-polarizing conditions. Results were normalized to Gapdh (*P < 0.05; mean ± SEM; n = 4). (C) Expression of Camk1, Camk2d, Camk2g, and Camk4 mRNA in naïve CD4+ T cells at different time points during Th0 or Th17 differentiation (*P < 0.05; mean ± SEM; n = 4–5). Data are representative of 3 independent experiments.

Our findings suggest that both the CaMK4-AKT-mTOR and the CaMK4-CREM-α axes are involved in the imbalance between Th17 cells and Tregs in autoimmune disease, thus revealing possible therapeutic targets for the treatment of Th17 cell–mediated inflammatory diseases.

Results

CaMK4 expression is induced preferentially during Th17 differentiation. CaMK4 expression and activity is increased in T cells from patients with SLE (19, 20) and MRL/lpr lupus-prone mice (refs. 19, 20, and Supplemental Figure 1; supplemental material available online with this article; doi:10.1172/JCI73411DS1). To gain a better understanding of the role that CaMK4 plays in T cell function, we isolated naïve CD4 T cells from MRL/lpr mice and stimulated them in the absence (Th0) or presence of polarizing cytokines to generate either Th17 cells (TGF-β + IL-6) or Tregs (TGF-β + IL-2) (10, 23). As shown in Figure 1A, T cell stimulation caused an increase in the levels of Camk4 at the protein level. This was particularly marked in T cells stimulated under Th17-polarizing conditions (Figure 1A, lane 3) and dampened by Treg-inducing cytokines (Figure 1A, lane 4). To determine whether this effect was specific for the Th17-polarizing program, we differentiated naïve CD4 T cells into Th1, Th2, and Th17 cells and Tregs and quantified Camk4 expression by real-time PCR. As shown in Figure 1B, Camk4 induction was significantly stronger in Th17 cells than in the other CD4 functional subsets. In order to clarify how the Th17-polarizing cytokines enhance the expression of CaMK4, we measured CaMK4 expression upon IL-1β, TGF-β, and/or IL-6 stimulation. Importantly, Camk4 mRNA was induced modestly by IL-6, TGF-β, or IL-1β alone but was induced significantly more by the combination of IL-6 and TGF-β and that of IL-6, TGF-β, and IL-1β. Induced Camk4 was inhibited by STAT3 or SMAD3 inhibitors, indicating that both signals are necessary for Camk4 induction under Th17 conditions (Supplemental Figure 2). Although IL-1β is crucial for the induction of Th17-producing cells (24), IL-1β did not have an additional effect when combined with Th17-promoting cytokines (IL-6 and TGF-β) in increasing Camk4 (Supplemental Figure 2). Camk4 is a member of a family of serine/threonine kinases that includes CaMK1, CaMK2γ, CaMK2δ, and CaMK4 (25). To determine the specificity of Th17-induced expression of Camk4, we stimulated naïve CD4 T cells under neutral (Th0) or Th17-inducing conditions and analyzed the expression of members of the Camk4 family by real-time PCR at different time points (Figure 1C). Expression of Camk1, Camk2g, and Camk2d did not differ when cells were stimulated under Th0- and Th17-polarizing conditions. In sharp contrast, Camk4 expression was significantly higher early during Th17 differentiation. These results indicate that Camk4 is preferentially induced during Th17 polarization. This phenomenon is particularly relevant, since patients with SLE and MRL/lpr mice have an increased abundance of IL-17–producing CD4^+ and CD4^− CD8^− T cells (5, 26) and IL-17 has been associated with organ damage in lupus (5, 23).

CaMK4 is necessary for in vitro Th17 differentiation. To determine whether CaMK4 plays a role in Th17 cell differentiation, we isolated naïve CD4 T cells from WT or Camk4^−/− OT-II mice and stimulated them under Th17-polarizing conditions. As shown in Figure 2A, absence of Camk4 caused a significant decrease in the percentage of IL-17–producing T cells (P = 0.0046). To expand these results, we transfected cells from Camk4-sufficient (Camk4^+/+)
Camk4 deficiency ameliorates EAE. To evaluate the relevance of Camk4 in an IL-17-dependent inflammatory condition, we induced EAE (28) in Camk4-sufficient (WT) and -deficient mice by immunizing with myelin oligodendrocyte glycoprotein (MOG35–55) (29). WT mice developed signs of EAE on day 11 and reached the peak of the disease on day 15 after immunization. In contrast, in Camk4−/− mice, disease onset was delayed and was significantly less severe when quantified as a clinical score (P = 0.0318; Figure 3A) or percentage of weight loss (P = 0.0464; Figure 3B).

To determine whether CaMK4 inhibition ameliorated EAE by decreasing the differentiation of Th17 cells, we immunized WT and Camk4−/− mice with MOG35–55 and quantified the frequency of IL-17−producing cells (P = 0.0321). However, reconstitution of Camk4 restored the IL-17 production defect, and, importantly, Camk4 overexpression led to increased numbers of IL-17−producing cells (P = 0.0378; Figure 2B).

KN-93 is an inhibitor of CaMK4 (27) that ameliorates disease in lupus-prone mice (21). We stimulated naive CD4 T cells in Th1-, Th2-, and Th17-polarizing conditions in the presence of 2 concentrations of KN-93 (4 and 10 μM). As shown in Figure 2C, KN-93 inhibited Th17 differentiation and IL-17 production in a dose-dependent manner (PBS vs. 4 μM, P = 0.0142; PBS vs. 10 μM, P = 0.0001). Consistent with these observations, mRNA levels of Th17 transcription factors and Th17 cell–associated cytokines were also decreased in the presence of KN-93 (Supplemental Figure 4). Conversely, its effects on the differentiation of Th1 and Th2 cells were negligible (Figure 2, C and D). Taken together, these data indicate that CaMK4 is a necessary element in Th17 differentiation and IL-17 production that can be modulated by a pharmacologic inhibitor of CaMK4.
of IL-17– and IFN-γ–producing cells 8 days later. As predicted by our in vitro results, CaMK4 deficiency reduced significantly the number of IL-17– CD4 T cells in the spleens and draining inguinal lymph nodes of immunized mice, without affecting the production of IFN-γ (Figure 3C). Independent histological analysis of spinal cords demonstrated significantly decreased inflammation and demyelination in Camk4−/− mice (Figure 4).

CaMK4 inhibition limits the production of IL-17 in MRL/lpr mice. CaMK4 expression and activity is increased in T cells from patients with SLE and lupus-prone mice (19, 20), and IL-17 has been suggested to play a role in target organ damage in lupus, including glomerulonephritis (30, 31). Therefore, we treated MRL/lpr mice with KN-93 for 10 weeks and examined IL-17A expression in spleens and lymph nodes during the peak of the disease (~16 weeks of age). KN-93 treatment led to a significant decrease in IL-17–producing CD4+ and CD4+CD8+ (double-negative [DN]) T cells in spleens and in lymph nodes from mice treated with KN-93 (Figure 5, A and B). In line with these observations, mRNA levels of Rorc, the master regulator of Th17 cells (32), were also reduced by pharmacologic inhibition of CaMK4 (Figure 5C). The inhibitory effects of KN-93 were specific for IL-17, since it did not modify the frequency of IFN-γ–producing cells or the expression of the Th1- and Th2-associated transcription factors Tbx21 and Gata3, respectively (Figure 5, B and C). KN-93 treatment decreased significantly the mortality of MRL/lpr mice (Figure 5D) as well as serum titers of anti–double-stranded DNA antibodies at 12 and 16 weeks of age and proteinuria at 16 weeks of age (Supplemental Figure 5), confirming the relevance of IL-17 inhibition in this lupus model.

Camk4 promotes transcription of Il17 through CREM-α. Methylation of CpG-DNA is associated with decreased transcription of neighboring genes (33). To investigate the mechanisms that regulate IL-17A expression during Th17 differentiation, we examined the CpG-DNA methylation of regulatory conserved noncoding sequences (CNSs) of the Il17 gene in CD4+ T cells from MRL/lpr and MRL/lpr.Camk4−/− mice (Supplemental Figure 6). After 24 hours of activation with anti-CD3 and anti-CD28 antibodies, CD4+ T cells from MRL/lpr mice exhibited low degrees of CpG-DNA methylation in all investigated regions of the Il17 locus (Figure 6A). In contrast, cells from MRL/lpr mice deficient in Camk4 had significantly higher levels of methylation (CNS1, P = 0.0382; CNS2, P = 0.0353). These results suggested that Camk4 regulates IL-17 production by controlling its transcription. Since the phosphorylation and DNA-binding activity of the transcription factor CREM-α is regulated by CaMK4 (19, 20) and CREM-α has been shown to modulate Il17 transcription in T cells from patients with SLE (34, 35), we hypothesized that Camk4 might control IL-17 expression through CREM-α. To evaluate this possibility, we analyzed the binding of CREM-α to consensus cAMP response element (CRE) sites within the Il17 promoters of CD4+ T cells from MRL/lpr and MRL/lpr.Camk4−/− mice by ChIP. As shown in Figure 6B, we detected reduced recruitment of CREM-α to CREs in the Il17 promoters of Camk4-deficient MRL/lpr mice. These results indicate that, through promoting the DNA-binding activity of CREM-α, Camk4 facilitates Il17 transcription.

To investigate whether CaMK4 regulates IL-17 expression at the transcriptional level, we cloned the IL17 promoter into a luciferase reporter system (36). This promoter region includes CRE and ROR element binding sites (35). As shown in Figure 6C, the cloned promoter region possessed transcriptional activity that was completely abrogated in cells treated with KN-93 or Camk4-specific siRNA, indicating that CaMK4 promotes the transcriptional activity of IL-17. As expected, the activity of the promoter was partially abrogated when the CRE site (~111/–104) was mutated and was completely lost when both the CRE and the ROR element binding sites (~140/–135) were mutated. CaMK4 inhibition by KN-93 or siRNA was still able to decrease the transcriptional activity of the promoter in the absence of the CRE site, suggesting that CaMK4 promotes Il17 transcription both through the CRE and the ROR element binding sites.

Camk4 promotes AKT/mTOR signaling. The activation of mTORC1 enhances Th17 differentiation (37) and disruption of mTORC1 caused by deletion of Rheb or Raptor impairs Th17 differentiation (38, 39). CaMKs, including Camk4, have been reported to modulate the AKT signaling pathway (40, 41). Therefore, CaMK4 might promote IL-17 production by facilitating AKT/mTOR signaling. To test this hypothesis, we first established the physical association between AKT and Camk4 by performing coimmunoprecipitation experiments (Figure 7A). Next, we analyzed the effect of KN-93 on the AKT/mTOR pathway activity induced by T cell stimulation. Western blots of cell lysates revealed that KN-93 significantly inhibited AKT phosphorylation in a dose-dependent manner (Figure 7B). KN-93 also inhibited the phosphorylation of p70S6, a substrate of mTOR (Figure 7C). These results were confirmed using T cells from Camk4−/− mice cultured in vitro under Th0- or Th17-polarizing conditions in the presence of OVA peptide (5 μM). As shown in Figure 7, D and E, phosphorylation of AKT and p70S6 was clearly decreased in the absence of Camk4. To further establish these findings, we incubated Jurkat T cells with KN-93 and quantified AKT and S6K phosphorylation by flow cytometry. KN-93 decreased AKT and S6K phosphorylation in Jurkat T cells (Supplemental Figure 7A). In concordance, overexpression of CaMK4 in Jurkat T cells induced increased AKT and S6K phosphorylation (Supplemental Figure 7B). Taken together, these results demonstrate that CaMK4 facilitates AKT/mTOR signaling. To determine whether CaMK4 promotes IL-17 production by facilitating AKT/mTOR signaling, we treated Camk4-overexpressing T cells with the mTORC1 inhibitor rapamycin (100 nM). mTORC1 blockade abrogated IL-17 production induced by Camk4 overexpression (Supplemental Figure 8).

Silencing of CaMK4 suppresses Th17 cells in human T cells. To determine the relevance of our findings in human T cells, we analyzed the effect of CaMK4 inhibition in T cells from healthy donors or patients with SLE. We first asked whether KN-93 can inhibit Th17 differentiation in controls. As expected, KN-93–treated T cells displayed a substantial reduction of IL-17–producing cells in a dose-dependent manner (Figure 8A). To determine the effects of CaMK4 inhibition on IL-17 expression in T cells from patients with SLE, we stimulated cells transfected with Camk4-specific or control siRNA with anti-CD3, anti-CD28, IL-6, and TGF-β. As shown in Figure 8B, CaMK4 inhibition decreased significantly IL17A and IL17F mRNA levels in cells from healthy donors and patients with SLE. Taken together, our results indicate that Camk4 positively regulates IL-17 production in T cells from healthy donors and patients with SLE.

Discussion

Recent data support the role of the effector cytokine IL-17A and Th17 cells in the pathogenesis of SLE and other autoimmune disorders, including MS. It has been noted that patients with SLE, including those with new-onset disease, display increased serum or plasma levels of IL-17A, expansion of IL-17–producing...
ing T cells in the peripheral blood, and infiltration of Th17 cells in target organs, including the kidneys (42, 43). Also, increased production of IL-17A in patients with SLE correlates with disease activity (44). Further, IL-17 has been implicated in the expression of organ pathology in lupus-prone mice (30, 44–46). Prior reports from our group have indicated the presence of IL-17–producing DN T cells in the kidneys of patients with SLE and those of the lupus-prone MRL/lpr and B6.lpr mice (26, 47). Tregs display suppressive activity against autoreactive lymphocytes, thus preventing or mitigating the onset of aberrant self-immune response (48). Most studies that examined the role of Tregs in SLE reported either reduced numbers or impaired function of circulating Tregs (49, 50). Accordingly, evidence suggests that aberrant T cell homeostasis and Th17/Treg imbalance represent an important key pathogenic player.

Here, we provide evidence that CaMK4 is important in the generation of Th17 cells and that elevated IL-17 cytokine production mediated by CaMK4 plays an important role in the fatal outcome in MRL/lpr mice and in EAE. Our work identifies CaMK4 as a critical molecule involved in the imbalance between Th17 and Tregs in autoimmunity.

Aberrant cytokine expression caused by an impaired transcriptional network is a hallmark of the pathogenesis of autoimmune diseases, including SLE and MS (51, 52). We reported recently that CaMK4 can activate the transcription factor CREM-α (19, 20), which mediates epigenetic remodeling of cytokine genes, including IL17 during the priming of CD4+ T cells from patients with SLE (35, 53). Consistent with this, MRL/lpr.Camk4−/− mice exhibited reduced CREM-α recruitment to the IL17 promoter, which led to decreased IL-17, arguing that the CaMK4-CREM-α

Figure 3
Camk4−/− mice are resistant to EAE. EAE was induced in WT and Camk4−/− mice by immunization with MOG35–55 emulsified in CFA. (A) The clinical score of EAE and (B) body weight in these mice were monitored (∗∗P < 0.01; mean ± SEM; cumulative results of 3 independent experiments with 3 to 5 mice per group). (C) Flow cytometry of intracellular IL-17 and IFN-γ at day 8 in CD4+ T cells obtained from mononuclear cells isolated from the draining inguinal lymph nodes (dLNs) and spleens of WT and Camk4−/− mice immunized with MOG35–55 emulsified in CFA to induce EAE and then activated in vitro with PMA and ionomycin (∗∗P < 0.01; mean ± SEM; n = 3–4). Data are representative of 2 independent experiments with 3 to 4 mice per group.
axis is active in lupus-prone mice and may be central to disease expression. To determine whether epigenetic changes are strain specific, we examined the methylation status of the Il17a loci from B6 and B6 Camk4 KO mice under Th17 conditions. We did not observe any significant differences in the methylation index in the B6 background (data not shown). Because we have already shown that CREM-α is expressed more in MRL/lpr mice (54) and T cells from patients with SLE (55), we speculate that Camk4 deficiency can inhibit CREM-α function only in the MRL background.

In this study, we demonstrate that Camk4 activity is the highest under Th17-polarizing conditions, and Kn-93, a known Camk4 inhibitor, can alter Th17 and Treg differentiation but not that of Th1 or Th2 in MRL/lpr mice. This specific involvement of Camk4 in the differentiation of Th17 cells solely, without affecting the differentiation of Th1 and Th2 cells, was unexpected and urges the consideration of pharmacologic inhibition of Camk4 in the treatment of Th17-dependent inflammatory diseases.

The PI3K/AKT/mTOR pathway is an intracellular signaling pathway that is important in several normal cellular functions that are also critical for tumorigenesis, including cellular proliferation, growth, survival, and mobility (56). It was reported recently that the PI3K-AKT-mTORC1-S6K axis positively regulates Th17 differentiation by promoting the nuclear translocation of RORγt (37,39). Here, we showed that pharmacologic inhibition of Camk4 by Kn-93 or genetic deletion of Camk4 in OT-II mice impairs the phosphorylation of S6K, indicating an importance of the Camk4/AKT/mTOR pathway in the regulation of Th17 differentiation. Prior reports have suggested that mTOR inhibitor, rapamycin, improved the clinical course of lupus nephritis and prolong survival in NZBW/F1 mice (57) as well as MRL/lpr mice (58). Moreover, this drug reduced disease activity in patients with SLE who had been treated unsuccessfully with other immunosuppressive medications (59). However, it is important to note that distinct side effects have been recognized, including interstitial pneumonitis, anemia associated with chronic inflammation, and severe forms of glomerulonephritis (60, 61). These antiinflammatory responses of mTOR inhibition have been mainly observed in monocytes, macrophages, and peripheral myeloid dendritic cells (62). Although AKT/mTOR pathway-related proteins are expressed in most immune cells, Camk4 is restricted to T cells, suggesting that inhibition of Camk4 may represent a more specific therapeutic option in Th17-mediated diseases, with potentially reduced side effects.

In conclusion, we have provided evidence that Camk4 plays a central role in reversing the balance between Th17 cells and Tregs in favor of Th17 cells and the development of organ damage in MRL/lpr mice as well as in mice provoked to develop EAE. Camk4 promotes Th17 cell differentiation and reduces the activity of Tregs. As depicted in Figure 9, Camk4 uses two distinct pathways, the AKT/mTOR pathway and one which increases the binding of CREM-α to the Il17a genes, followed by epigenetic modulation of their activity (63). We have not addressed the relative contribution of each pathway in the differentiation of Th17 cells and whether one or the other is sufficient alone for the production of IL-17. What is important though is the fact that Camk4 is upstream of both of them and that its inhibition will avert IL-17–instigated inflammation.

**Methods**

**Mice.** Female MRL/MpJ-Tnfrsf6(lpr) (MRL/lpr), B6.129X1-Camk4tm1Tch/J, B6, OT-II (C57BL/6-Tg(Tera.Tcrb)425Bhn/J), and MRL/MPJ mice were purchased from The Jackson Laboratory. MRL/lpr.Camk4−/− mice have been described previously (20). OT-II.Camk4−/− mice were made by crossing B6 mice with OT-II mice. MRL/lpr mice were administrated with Kn-93, a Camk4 inhibitor (Calbiochem), as previously reported (21). Animals were sacrificed at the end of their 6th or 16th week of life. Mice were maintained in an SPF animal facility (Beth Israel Deaconess Medical Center). Experiments were approved by the Institutional Animal Care and Use Committee of Beth Israel Deaconess Medical Center.

**In vitro T cell differentiation.** Spleens and lymph nodes were excised from mice, and single-cell suspensions were obtained by teasing the organs through a nylon mesh. Naïve CD4+ T cells from the spleens and lymph nodes were then purified by magnetic cell sorting (CD4+CD62L– T Cell Isolation Kit II; Miltenyi Biotec) or by FACS Aria II cell sorter (BD Biosciences); the purity of

---

**Figure 4**

Camk4−/− mice display less inflammation and demyelination in EAE. Spinal cord sections from WT and Camk4−/− mice obtained at 14 days after immunization. Sections were stained with (A and B) H&E to assess inflammation and (D and E) luxol fast blue to assess myelin content. Arrows indicate inflammatory cellular infiltrates. Scale bars: 50 µm (top rows); 200 µm (bottom rows). Quantitative cumulative data (n = 4 mice per group) are shown in C (**p < 0.05).
isolated T cell populations routinely exceeded 95%. Naïve T cells were stimulated with plate-bound goat anti-hamster antibodies, soluble anti-CD3 (0.25 μg/ml, clone 145-2C11; Biolegend) and anti-CD28 (10 μg/ml, clone 37.51; Biolegend), in the presence of IL-12 (20 ng/ml; R&D Systems) and anti–IL-4 (10 μg/ml; C17.8; Biolegend) for the generation of Th1 cells; IL-6 (100 ng/ml; R&D Systems), TGF-β1 (3 ng/ml; R&D Systems), anti–IL-4 (10 μg/ml; C17.8; Biolegend), and anti–IFN-γ (10 μg/ml; XMG1.2; Biolegend) for the generation of Tregs. Assays with splenocytes from OT-II mice were done using the OVA323−339 peptide (5 μM; Bio-Synthesis Inc.). For signal transduction studies, STAT3 inhibitor (10 μM; Calbiochem), SMAD3 inhibitor (10 μM; Calbiochem), and mTOR inhibitor rapamycin (100 nM; Calbiochem) were added to cultures.

**EAE disease models.** Mice were immunized with MOG35−55 peptide emulsified in CFA (Sigma-Aldrich) containing 4 mg/ml Mycobacterium tuberculosis extract H37Ra (Difco) in 100 μl per mouse s.c. distributed between the 2 hind flanks and above the sternum on day 0. On days 0 and 2, 50 μg pertussis toxin (List Biological Laboratories) was given i.v. Subsequently, these mice were treated with KN-93 or PBS twice a week. Mice were monitored daily and clinical scores were given as follows: 1, limp tail; 2, hind-limb paresis; 3, hind-limb paralysis; 4, tetraplegia; 5, moribund.

**Histological staining and analysis.** Spinal cords (10% formalin fixed) were stained with H&E for detection of inflammatory infiltrates and luxol fast blue for myelin detection. Histological sections were scored by an investigator blinded to experimental group as follows: 0, no infiltration (<50 cells); 1, mild infiltration of nerve or nerve sheath (50–100 cells); 2, moderate infiltration (100–150 cells); 3, severe infiltration (150–200 cells); 4, massive infiltration (>200 cells).

**Intracellular cytokine staining.** For intracellular cytokine staining, cells were isolated as described above and were stimulated for 4 hours in culture medium containing PMA (50 ng/ml; Sigma-Aldrich), ionomycin (1 mg/ml; Sigma-Aldrich), and monensin (GolgiStop; 1 ml/ml; BD Biosciences). After staining of surface markers CD3e (17A2, eBioscience), CD4 (GK1.5, Biolegend), CD8α (53-6.7, eBioscience), or TCRβ (H57-597, BioLegend) for 30 minutes at 4°C, cells were fixed and made permeable with Cytofix/Cytoperm and Perm/Wash buffer according to the manufacturer’s instructions (BD Biosciences). All antibodies to cytokines (anti–IFN-γ XMG1.2, anti–IL-4 11B11, and anti–IL-17A JC11-18H10.1) were from BioLegend. For the detection of phosphorylated signaling proteins, lymphocytes were fixed with 1.5% paraformaldehyde, followed by permeabilization with methanol and staining with antibodies to S6 phosphorylated at Ser 235 and Ser 236 (D57.2.2E; Cell Signaling Technology) and AKT phosphorylated at Ser 473 (D9E; Cell Signaling Technology).
RNA isolation and real-time RT-PCR. Total mRNA was isolated from spleen cells using the RNeasy Mini Kit (Qiagen) and then cDNA was synthesized using cDNA EcoDry Premix (Clontech) for PCR amplification. Expression was normalized to Gapdh. All primers and probes were from Applied Biosystems or OriGene: Gata3 (Mm01337569_m1), Tbx21 (Mm00450960_m1), Rorc (Mm00441144_g1), Il17a (Mm00439619_m1), Il17f (Mm00521423_m1), Il12 (Mm00051760_m1), Il22 (Mm00444241_m1), Camk1 (Mm00519436_m1), Camk2g (Mm00499266_m1), Camk4 (Mm01135329_m1), Gapdh (Mm99999915_g1), Il17a (Hs00936345_m1), and GAPDH (4310884E). Gene expression was assessed by comparative C\textsubscript{T} method.

ELISA. Splenic naive CD4\textsuperscript{+}CD62\textsuperscript{+} T cells were stimulated as described above. After 72 hours, IFN-\gamma, IL-4, and IL17A were measured in supernatants by ELISA (BioLegend). Serum anti-dsDNA antibody concentration was detected by the mouse anti-dsDNA IgG ELISA kit (Alpha Diagnostic Intl. Inc.). Urinary albumin was quantified by ELISA (Bethyl Laboratories).

Western blotting. Splenocytes or T cells were lysed in RIPA buffer at 4°C for 30 minutes. After centrifugation (16,400 g; 30 minutes; 4°C), supernatants were loaded.
**Figure 7**
Inhibition of CaMK4 decreased Th17 differentiation through the blocking of the AKT/mTOR signaling pathway. (A) Immunoprecipitation and protein immunoblot analysis of AKT expression is shown. Jurkat T cells were stimulated with anti-CD3 and anti-CD28 antibodies for 20 minutes. Cell lysates were then prepared and immunoprecipitated with anti-CaMK4 or with a control rabbit antibody. The immunoprecipitates were then analyzed by immunoblotting using AKT antibody. The data are representative of 2 independent experiments. Western blotting analysis of (B) phospho-AKT and (C) phospho-S6K in OT-11 cells (WT or Camk4−/− mice in unstimulated and Th17 conditions for the indicated times. The graphs in (B–E) show cumulative data of densitometry (*P < 0.05; **P < 0.01; mean ± SEM; n = 3–4). Data are representative of 3 independent experiments with 3 to 4 mice per group.

**Gene expression plasmids transfections.** T cells from OT-II WT mice or OT-II Camk4−/− mice were cultured for 16 to 18 hours in RPMI/Th0 conditions. 2 million stimulated cells were transiently transfected with 2 μg of mouse CaMK4 expression vectors (CaMK4 expression plasmid under the control of the CMV promoter) or empty vector (pCMV6) from OriGene Technologies. Transfections were performed using the Amaxa Mouse T Cell Nucleofector Kit with the X-001 program (Amaxa) according to the manufacturer’s protocol. After 4 hours recovery at 37°C, cells were stimulated in Th17 conditions in RPMI media.

**Methylated CpG-DNA immunoprecipitation.** The methylated CpG-DNA immunoprecipitation assay was carried out according to the manufacturer’s instructions (Zymo Research). Briefly, genomic DNA from T cells obtained from MRL/lpr mice or MRL/lpr Camk4−/− mice was purified using the AllPrep RNA/DNA/Protein Mini Kit (Qiagen), sheared to fragments of approximately 200 bp using DNA Shearase (Zymo Research). Subsequently, 100 ng sheared genomic DNA was used for methylated CpG-DNA immunoprecipitation. Methylated DNA was recovered and subjected to PCR analysis. Real-time PCR primer sequences are given in Supplemental Table 1.

**ChIP assays.** Polyclonal anti–CREM-α antibody detecting mouse CREM-α has been described before (19). Nonspecific normal rabbit IgG was obtained from Invitrogen. ChIP experiments were carried out with the Magnify ChIP assays (Life Technologies) according to the manufacturer’s protocol. Briefly, 2 million cells were cross-linked with 1% formaldehyde, washed with cold PBS, and lysed in buffer containing protease inhibitors (Roche). Cell lysates were sonicated to shear DNA and sedimented, and diluted supernatants were immunoprecipitated with the indicated antibodies. 10% of the diluted supernatants were kept as “input” (input represents PCR amplification of the total sample). Real-time PCR primer sequences are given in Supplemental Table 1. The amount of immunoprecipitated DNA was subtracted from the amount of amplified DNA, which was bound by the nonspecific normal IgG and subsequently calculated as relative to the respective input DNA.

**Immunoprecipitation.** Immunoprecipitation was performed with the Dynabeads Protein G Immunoprecipitation Kit (Life Technologies) according to the manufacturer’s protocol. Briefly, cell lysates were prepared as described above, and proteins were immunoprecipitated by incubation of lysates with 3 μg CaMK4 antibody or control rabbit IgG overnight at 4°C and pull-down of antibody-protein precipitates with Dynabeads Protein G.
Obtained T cells from these groups were treated with KN-93 or transfected with CAMK4-specific or control siRNA as described previously (20, 21). After 24 hours, cells were stimulated with plate-bound goat anti-mouse antibodies (Chemicon Millipore), soluble anti-CD3 (5 μg/ml, clone OKT3; BioXcell), anti-CD28 (2.5 μg/ml, clone 28.2; BioLegend), IL-6 (50 ng/ml, R&D Systems), and TGF-β1 (5 ng/ml, R&D Systems) and cultured for 96 hours.

**Figure 8**
Silencing of CaMK4 decreases Th17 cells in patients with SLE. (A) T cells from healthy donors were stimulated in Th17 conditions in the absence or presence of KN-93 for 72 hours, and IFN-γ-producing CD4+ T cells or IL-17A-producing CD4+ T cells were determined by intracellular cytokine staining. A representative experiment from 1 of 4 donors is shown. (B) T cells from normal controls (n = 4) or patients with SLE (n = 6) were transfected with either control siRNA or CAMK4-specific siRNA. 24 hours after transfection, cells were differentiated for 72 hours under Th17 conditions and analyzed by quantitative real-time PCR of IL17A or IL17F mRNA (*P < 0.05; mean ± SEM).

**Figure 9**
Model depicting the molecular mechanisms whereby CaMK4 controls the expression of IL-17. Engagement of the TCR causes an increase in intracellular calcium that leads to the activation of CaMK4. Active CaMK4 translocates to the nucleus, in which it phosphorylates CREM-α, which can bind to Il17 promoter. On the other hand, active CaMK4 also phosphorylates AKT, resulting in the activation of the AKT/mTOR/S6K pathway. S6K interacts with RORγ and enhances its nuclear translocation, leading to transcriptional control of IL-17.
10^6 cells of plasmid DNA using the Amaxa Human T cell Nucleofector Kit (Lonzza) and an Amaxa Nucleofector II device (protocol U014; Lonza). Each reporter experiment included 10 ng lenrrusera cerrnil as a internal control. 12 hours after transfection, cells were stimulated with anti-CD3 and anti-CD28 antibodies in the absence or presence of KN-93 for 6 hours and collected and lysed, and Luciferase activity was quantified using the Promega Dual Luciferase Assay System (Promega) following the manufacturer’s instructions.

Infection with lentivirus. Jurkat T cells were infected with CaMK4-inducible lentivirus particles (LVP133; GenTarget) or negative control lentiviral particles (RFP-bsd; GenTarget). 3 days after transfection, cells were stimulated with anti-CD3 and anti-CD28 antibodies, and phosphorylation of AKT and S6K was examined by flow cytometry.

Statistics. Student’s two-tailed t tests and Mann Whitney u test. Statistical analyses were performed in GraphPad Prism 6.0b software. P < 0.05 was considered significant.

Acknowledgments

This work was supported by NIH grant R01AR064350 (to G.C. Tsokos). We wish to thank Maria Tsokos for evaluating the spinal cord histology.

Received for publication October 4, 2013, and accepted in revised form January 23, 2014.

Address correspondence to: George C. Tsokos, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Ave., CLS-937, Boston, Massachusetts 02215, USA. Phone: 617.735.4160; Fax: 617.735.4170; E-mail: gtsokos@bidmc.harvard.edu. Or to: Jose C. Crispin, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Ave., Dana-517C, Boston, Massachusetts 02215, USA. Phone: 617.667.2786; Fax: 617.667.2785; E-mail: jcrispin@bidmc.harvard.edu.